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The immediate-early gene egr-1 (also known as NGFI-A,
krox24, zif268, and tis8) encodes a transcription factor containing three tandem zinc finger motifs that bind to GC-rich DNA
elements in the promoters of a range of target genes to activate
their transcription (1). egr-1 expression is elicited in response to
a diverse variety of signals, including growth factors, cytokines,
lipopolysaccharide, serum, irradiation, stress, hypoxia, and
urea, in many cell types, including neuronal cells, epithelial
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cells, fibroblasts, myeloid cells, and T and B lymphocytes (2–9).
In many studies, Egr-1 was found to be associated with cell
proliferation, differentiation, and transformation (3, 10 –14).
Egr-1 was also shown to induce apoptosis in certain cell types in
response to irradiation by activating p53 (15) or PTEN expression (16). Yu et al. (17) reported that differential post-translational modification of Egr-1 (acetylation versus phosphorylation) is likely responsible for its different roles in promoting
growth versus apoptosis in response to serum and UV irradiation. Moreover, Egr-1 is shown to be important for production
of pro-inflammatory cytokines such as interleukin-1␤, interleukin-13, and tumor necrosis factor as well as chemokines
(18 –20).
In normal mature B lymphocytes, signaling through the B cell
receptor (BCR)2 induces rapid and transient expression of egr-1
(6), but its importance for subsequent B cell activation and proliferation is unknown. In contrast, BCR engagement in immature B lymphoma cells fails to induce egr-1 expression, and the
lymphoma cells undergo growth inhibition and apoptosis (21).
Thus, BCR-induced positive versus negative signals are
reflected in the differential expression of egr-1. Interestingly, an
immature B lymphoma cell line (BKS-2) constitutively
expresses high levels of Egr-1, and antisense oligodeoxynucleotides (ODNs) to Egr-1 inhibit BKS-2 cell growth (14). BCR
signaling, which causes growth arrest and apoptosis of BKS-2
cells, also down-regulates egr-1 (14). The down-regulation of
Egr-1 and growth inhibition caused by anti-IgM antibody are
reversed by CpG ODN (22). These data suggest a positive correlation between the levels of Egr-1 and growth of B lymphoma
cells. An examination of the microarray data published by
Alizadeh et al. (23) revealed that egr-1 expression is elevated in
⬃35% of human diffuse large B lymphoma cells, supporting the
notion that Egr-1 is important for B lymphoma cell growth.
Several studies in different cell lines have shown that the
rapid induction of Egr-1 with various stimuli is mediated

2

The abbreviations used are: BCR, B cell receptor; ODNs, oligodeoxynucleotides; ERK, extracellular signal-regulated kinase; MEK, mitogen-activated
protein kinase/extracellular signal-regulated kinase kinase; JNK, c-Jun
N-terminal kinase; MAPK, mitogen-activated protein kinase; EGFP,
enhanced green fluorescent protein; ICAM-1, intercellular adhesion molecule 1; FCS, fetal calf serum; FACS, fluorescence-activated cell sorter;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PMA, phorbol
12-myristate 13-acetate; SREs, serum response elements.
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Cross-linking of the B cell receptor (BCR) on the immature B
lymphoma cell line BKS-2 induces growth inhibition and apoptosis accompanied by rapid down-regulation of the immediate-early gene egr-1. In these lymphoma cells, egr-1 is expressed
constitutively and has a prosurvival role, as Egr-1-specific antisense oligonucleotides or expression of a dominant-negative
inhibitor of Egr-1 also prevented the growth of BKS-2 cells.
Moreover, enhancement of Egr-1 protein with phorbol 12-myristate 13-acetate or an egr-1 expression vector rescued BKS-2
cells from BCR signal-induced growth inhibition. Nuclear
run-on and mRNA stability assays indicated that BCR-derived
signals act at the transcriptional level to reduce egr-1 expression.
Inhibitors of ERK and JNK (but not of p38 MAPK) reduced egr-1
expression at the protein level. Transcriptional regulation
appears to have a role because egr-1 promoter-driven luciferase
expression was reduced by ERK and JNK inhibitors. Promoter
truncation experiments suggested that several serum response
elements are required for MAPK-mediated egr-1 expression.
Our study suggests that BCR signals reduce egr-1 expression by
inhibiting activation of ERK and JNK. Unlike ERK and JNK, p38
MAPK reduces constitutive expression of egr-1. Unlike the
immature B lymphoma cells, normal immature B cells did not
exhibit constitutive MAPK activation. BCR-induced MAPK
activation was modest and transient with a small increase in
egr-1 expression in normal immature B cells consistent with
their inability to proliferate in response to BCR cross-linking.

Mechanism of BCR-induced Down-regulation of Egr-1

EXPERIMENTAL PROCEDURES
Reagents—The MEK1/2 inhibitors PD98059 and U0126 and
the p38 MAPK inhibitor SB203580 were purchased from Calbiochem. SP600125, an anthrapyrazolone inhibitor of JNK, was
obtained as a gift from Dr. B. Bennett (Celgene, San Diego, CA).
All three inhibitors were dissolved in Me2SO to make a 20 mM
stock solution and diluted in culture medium before use. Phospho-specific antibodies against JNKs (Thr183/Tyr185), ERKs
(Thr202/Tyr204), and p38 (Thr180/Tyr182) were obtained from
Cell Signaling Technology, Inc. (Beverly, MA). The antibody to
total p38 was also obtained from Cell Signaling Technology,
Inc. Antibodies to total JNK1, ERK, Egr-1 (clone C-19), and the
N-terminal domain of the Wilms tumor protein WT1 (clone
F-6) were obtained from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA). Anti-␤-actin monoclonal antibody was obtained
from Sigma. The effectiveness and specificity of PD98059 for
MEK1/2 and SP600125 for JNK have been demonstrated by
previous studies (29 –32).
DNA Plasmids and Antisense ODNs—The egr-1 expression
plasmid pBX-Egr1 containing the full-length Egr-1 cDNA
driven by the SV40 promoter has been described (33). The
dominant-negative Egr-1 construct WT1-EGR1 was cloned
into the retroviral vector LZRSpBMN-linker-internal ribosomal entry site-enhanced green fluorescent protein (EGFP)
encompassing a ribosomal entry site allowing for cap-independent
translation of EGFP (40). LucA–D constructs containing different
egr-1 promoter regions linked to a firefly luciferase gene have been
described previously (5). To create the p903luc construct, the egr-1
promoter sequence from ⫺903 to ⫹65 was excised from the
pBL903 plasmid described by McMahon and Monroe (34) by XbaI
and ligated into the NheI-treated promoterless firefly luciferase
vector pGL3b (pluc) from Promega (Madison, WI). To create the
p395luc construct, the egr-1 promoter sequence from ⫺395 to
DECEMBER 29, 2006 • VOLUME 281 • NUMBER 52

⫹65 was excised from the pBL395 plasmid described by McMahon and Monroe (34) by XbaI and SalI double digestions and
ligated into the NheI- and XhoI-treated plasmid pGL3b. To create
the p242luc construct, the egr-1 promoter sequence from ⫺242 to
⫹65 was PCR-amplified from the pBL395 vector, and the PCR
fragment was treated with XhoI and SalI and ligated into the XhoItreated pGL3b vector. To create the actin promoter-driven Renilla
luciferase construct (pActinRluc), the Renilla luciferase gene was
excised from the pRL-SV40 vector (Promega) by HindIII and
BamHI enzyme digestions and ligated into the pH␤-Apr1 plasmid
(a gift from Dr. Daret St. Clair, University of Kentucky) that had
been treated with the same two enzymes. All DNA clones were
confirmed by DNA sequencing. In experiments aimed at blocking
egr-1 expression, a phosphorothioate-capped antisense Egr-1
ODN (AS2AS295, 5⬘-CTTGGCCGCTGCCAT-3⬘), a control
phosphorothioate-capped nonsense Egr-1 ODN (NS281,
5⬘-GAGCGACCAGGCCCTACCGT-3⬘), and a phosphorothioate-capped antisense ODN against ICAM-1 (ISIS3082, 5⬘-TGCATCCCCCAGGCCACCAT-3⬘) were used. The antisense
ODNs for Egr-1 and ICAM-1 have been described previously
(35, 36).
Mice, Cell Lines, and Cell Preparation—Neonatal (9 –11 days
old) and young adult (2–3 months old) BALB/c mice were purchased from Harlan Sprague Dawley, Inc. (Indianapolis, IN).
Female CBA/N (Xid) mice were purchased from The Jackson
Laboratory (Bar Harbor, ME). Mice were housed under specific
pathogen-free conditions in micro-isolator cages. B cells were
purified by two methods. For MAPK experiments, splenic cells
were pooled from at least one litter of neonatal mice and purified by negative selection using magnetic cell sorter (MACS威) B
cell enrichment MicroBeads (Miltenyi Biotec, Bergisch Gladbachor, Germany). As previously found in our laboratory (37),
the splenic B cells from neonatal mice were predominantly
immature B cells. The purified B cells were ⬃90% B220 and
AA4.1 double positive as determined by flow cytometry. The
purified B cells were rested in IF-12 medium (1:1 mixture of
Iscove’s modified Dulbecco’s medium and Ham’s F-12
medium) in a 37 °C incubator at 5% CO2 for 1 h and then treated
with or without 20 g/ml anti-IgM antibody for different time
periods. Cells were harvested and lysed for Western blot analysis as described below. For Egr-1 RNA analysis, immature and
mature B cells from neonatal and young adult mice, respectively, were enriched by panning with goat anti-IgM antibody
immobilized on tissue culture-treated dishes as described previously (37). Purified B cells were treated with anti-IgM antibody for different time periods and harvested for RNA extraction as described below.
The isolation and characterization of the immature B lymphoma cell line BKS-2 has been described (38). Briefly, BKS-2
cells were grown in female CBA/N (Xid) mice as splenic tumors
by intravenous injection. These cells attained maximal growth
(2– 6 ⫻ 108 cells/mouse spleen) in ⬃7–10 days and were collected for experimental use at this stage. Depletion of host
residual T cells was performed using a mixture of anti-Thy1.2,
anti-CD4 (L3T4), and anti-CD8 (Lyt2) antibodies, followed by
rabbit complement treatment as described previously (39).
BKS-2 cells were cultured in IF-12 medium and 10% fetal calf
serum (FCS; Atlanta Biologicals, Norcross, GA). CH12.Lx lymJOURNAL OF BIOLOGICAL CHEMISTRY
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through ERK1/2. In cardiomyocytes, estrogen induces the
rapid induction of Egr-1 mRNA through activation of ERK1/2
(24). In human monocytes, the rapid induction of Egr-1 by
lipopolysaccharide is dependent on the Ras/Raf-1/MEK/ERK
pathway (19). In erythroleukemia cells, the erythropoietin-induced expression of egr-1 is mediated through the ERK1/2
pathway (25). In T cell hybridoma, ERK activation is required
for induction of egr-1 promoter activity by T cell receptor stimulation (26). In splenic B cells, the induction of Egr-1 in
response to BCR signaling is also mediated through the Ras/
Raf-1/MAPK pathway (27). However, factors that govern the
constitutive expression of egr-1 in certain lymphoma cells or
mechanisms that result in BCR-mediated down-regulation of
Egr-1 are not known.
Here, we found that constitutive expression of egr-1 in B
lymphoma cells is dependent on constitutively active ERK and
JNK pathways. The growth of B lymphoma cells is inhibited by
blocking the Egr-1 upstream pathways (ERK and JNK) or inhibiting Egr-1 directly by retrovirus-mediated expression of the
dominant-negative construct WT1-EGR1 (28). Furthermore,
we found that Egr-1 expression is regulated by MAPK at the
level of transcription and that the down-regulation of Egr-1 by
BCR is through down-regulation of ERK and JNK activities.

Mechanism of BCR-induced Down-regulation of Egr-1
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ern blot analysis examining the expression of WT1-EGR1 and endogenous
Egr-1 pro-teins for both cell lines. Cells (5 ⫻ 106) were harvested 48 h posttransfection and used for Western analysis. An antibody against the N-terminal domain of the Wilms tumor protein WT1 (clone F-6) was used to detect
WT1-EGR1 protein.
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FIGURE 1. Inhibition of Egr-1 protein or function causes growth inhibition
of BKS-2 cells. A, an antisense Egr-1 oligomer without the tetra-G motif inhibits the growth of BKS-2 cells. BKS-2 cells (2–3 ⫻ 104/well) were cultured with
the indicated concentrations of nonsense (f) or antisense (⽧) Egr-1 oligomer
or an antisense oligomer to ICAM-1 (Œ) for 48 h. Cells were pulsed with
[3H]thymidine during the last 4 h of culture. Data points indicate the
mean ⫾ S.E. of the percent [3H] incorporation compared with the medium
group of triplicate cultures from a representative experiment. The actual
counts for the medium group were 66,962 ⫾ 11,612 cpm. The first point at
0.01 M is really with no oligomer, but it was given this value because the
log scale does not allow a zero value. This experiment was repeated two
times with similar results. *, p ⬍ 0.02 for antisense Egr-1 versus either
nonsense Egr-1 or antisense ICAM-1 data points. Inset, Western blot analysis of Egr-1 expression after BKS-2 cells were treated with 2 M nonsense
(NS) or antisense (AS) Egr-1 oligomer for 24 h. The same blot was stripped
and reprobed for ␤-actin as a loading control. The ratio of the densitometry of the Egr-1 band to the actin band is shown below the Western blot.
B and C, retrovirus-mediated expression of WT1-EGR1, a dominant-negative inhibitor of EGR1, inhibits the growth of BKS-2 and CH12.Lx lymphoma cells, respectively. Left panels, BKS-2 (B) or CH12.Lx (C) lymphoma
cells were transfected with either the empty retroviral vector LZRS
expressing only EGFP or the vector expressing both EGFP and WT1-EGR1.
The GFP⫹ cells were sorted 72 h post-transfection and cultured for 48 h.
Cells were pulsed with [3H]thymidine during the last 4 h of culture. Data
points indicate the mean counts ⫾ S.E. of triplicate cultures from a representative experiment. This experiment was repeated three times with similar results. *, p ⬍ 0.005 versus the LZRS control vector. Right panels, West-

phoma cells were obtained from Dr. Gail Bishop (University of
Iowa) and cultured in RPMI 1640 medium supplemented with
10% FCS.
Proliferation Assay—BKS-2 cells (3 ⫻ 104/well) were cultured in 96-well flat-bottom microtiter plates (Costar, Cambridge, MA) in 200 l of IF-12 medium and 10% FCS. Cultures
were treated with varying doses of SP600125, PD68059, or
SB203580 or an equivalent concentration of Me2SO; incubated
at 37 °C and 5% CO2 for a total of 48 h; and pulsed with 1 Ci of
[3H]thymidine (PerkinElmer Life Sciences) during the last 4 h
of the culture period. The cells were harvested onto filter mats
using a cell harvester (Packard Instrument Co., Meriden, CT).
The levels of radionucleotide incorporation were measured
with a Matrix 96 ␤-radiation counter (Hewlett-Packard,
Downers Grove, IL). Results are presented as the means ⫾
S.E. of triplicate cultures. The percent control response is
defined as (cpm in the treated group/cpm in the untreated
group) ⫻ 100.
Retroviral Transfection of B Lymphoma Cells and Fluorescence-activated Cell Sorter (FACS) Analysis—Retroviral vectors
were transiently transfected into Phoenix-E packaging cells
using the Lipofectamine Plus transfection system (Invitrogen)
according to the manufacturer’s protocol. Virus-containing
supernatants were harvested from transfected Phoenix-E cells
for transfection of B lymphoma cells. B lymphoma cells were
washed and resuspended in serum-free Opti-MEM I (low
serum medium; Invitrogen), and single cell suspensions at a
concentration of 1 ⫻ 106 cells/ml were spin-infected for 2 h at
30 °C in 2 ml of Polybrene (Sigma)-treated virus-containing
supernatant (40). At the end of the 2-h infection period, the
virus-containing supernatant was discarded, and fresh medium
was added to the B lymphoma cells. For Western analysis, 5 ⫻
106 cells were harvested 48 h post-transfection, and cell pellets
were lysed in 100 l of cell lysis buffer (20 mM Tris (pH 7.5), 150
mM NaCl, l mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM
sodium pyrophosphate, 1 mM ␤-glycerolphosphate, 1 mM
Na3VO4, 1 g/ml leupeptin, and 1 mM PMSF). For proliferation
assay, GFP⫹ cells were sorted by a FACS MoFlo flow cytometer
(DakoCytomation, Fort Collins, CO) 72 h post-transfection and
used as described above.
Nuclear Run-on Assay—Nuclei were isolated from BKS-2
cells treated with or without anti-IgM antibody for 1 h, and
nuclear run-on assay was performed as described previously
(41). The newly synthesized mRNA molecules were labeled by
incubating nuclei with [32P]UTP. Labeled RNA was hybridized
to filters that had been cross-linked with Egr-1, c-Myc, or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA or
the BlueScript empty vector. The amounts of nascent Egr-1,
c-Myc, and GAPDH mRNAs present in cells upon different
treatments were analyzed by dot blot analysis. The amounts of
Egr-1 and c-Myc mRNAs were normalized to that of GAPDH
mRNA.

Mechanism of BCR-induced Down-regulation of Egr-1

Western Blot Analysis—After different treatments, BKS-2
cells (4 ⫻ 106) were cultured at 1 ⫻ 106/ml in 6-well plates
(Costar). Cell pellets were lysed in 90 l of cell lysis buffer on ice
for 30 min, and Western blotting was performed as described
(14, 31). The blots were developed with Pico chemiluminescence substrate (Pierce) and exposed to Kodak X-Omat films,
which were scanned with a Hewlett-Packard ScanJet 6300C
flat-bed scanner. Alternatively, the blots were scanned by a
Eastman Kodak Image Station 2000RT. For reprobing, membranes were stripped using a solution containing 62.5 mM TrisDECEMBER 29, 2006 • VOLUME 281 • NUMBER 52

RESULTS
Inhibition of Egr-1 by Antisense ODNs or Retrovirus-mediated Expression of WT1-EGR1 Inhibits B Lymphoma Cell
Growth—A previous study showed that egr-1 is constitutively
expressed in BKS-2 lymphoma cells and that inhibition of egr-1
by specific antisense ODNs causes growth inhibition and apoptosis of BKS-2 (14). Because the antisense ODNs used in this
study contained tetra-G motifs (GGGG) that could form triple
helical structures leading to sequence-independent inhibition
(42, 43), we used two additional approaches to study the importance of Egr-1 for lymphoma cell growth. First, an egr-1-specific
antisense ODN without the tetra-G motif was used. Western blot
analysis showed that the Egr-1 antisense ODN caused a reduction
in endogenous Egr-1 protein (Fig. 1A, inset). Cell proliferation
measured by [3H]thymidine incorporation showed that this Egr-1
antisense ODN inhibited the growth of BKS-2 cells (Fig. 1A). Used
as controls, both an Egr-1 nonsense ODN and an antisense ODN
against ICAM-1 did not cause growth inhibition of BKS-2 cells.
Second, retrovirus-mediated expression of WT1-EGR1, a domiJOURNAL OF BIOLOGICAL CHEMISTRY

39809

Downloaded from http://www.jbc.org/ by guest on February 20, 2019

FIGURE 2. PMA overcomes anti-IgM antibody-mediated growth inhibition by up-regulating Egr-1. A, anti-IgM antibody inhibits the growth of
BKS-2 cells. BKS-2 cells (3 ⫻ 104/well) were cultured with the indicated concentrations of anti-IgM antibody for 48 h. Cells were pulsed with [3H]thymidine during the last 4 h of culture. Data points indicate the mean counts ⫾ S.E.
of triplicate cultures from a representative experiment of three independent
experiments. B, time course of Egr-1 protein expression following anti-IgM
antibody cross-linking. BKS-2 cells (4 ⫻ 106) were cultured in the absence or
presence of 5 g/ml anti-IgM antibody for 1, 5, and 24 h. Cells were harvested
and lysed. Protein lysates were analyzed by Western blotting using anti-Egr-1
antibody. The same blot was stripped and reprobed for ␤-actin as a loading
control. C, PMA reverses the BCR-mediated growth inhibition of BKS-2 cells
and up-regulates Egr-1 protein. BKS-2 cells (3 ⫻ 104/well) were cultured in the
absence or presence of the indicated concentrations of PMA and 0.5 g/ml
anti-IgM antibody for 48 h. Cells were pulsed with [3H]thymidine during the
last 4 h of culture. Data points indicate the mean counts ⫾ S.E. of triplicate
cultures from a representative experiment of three independent experiments. Inset, Western blot of protein lysates from BKS-2 cells treated with or
without 0.5 g/ml anti-IgM antibody in the absence or presence of 3 ng/ml
PMA for 5 h. DMSO, dimethyl sulfoxide.

HCl, 2% SDS, and 100 mM ␤-mercaptoethanol at 62 °C for 10
min. The relative integrated absorbance of the protein bands
was estimated using Scion Image software. Band intensities
were normalized by dividing the intensity of phosphorylated
protein by that of total protein or by dividing the intensity of the
protein of interest by that of ␤-actin.
Quantitative RT-PCR—After various treatments, BKS-2 cells
(5 ⫻ 106) were used for RNA extraction with the QIAamp RNA
blood mini kit (Qiagen Inc.). 2 g of total RNA was used to
make cDNA with Superscript II reverse transcriptase (Invitrogen) according to the manufacturer’s protocol. Real-time PCR
was performed on an ABI Prism 7000 system using TaqManbased egr-1-specific primers and probe (Applied Biosystems,
Foster City, CA). The GAPDH- or ␤-actin-specific primers and
probe were used to control for loading (Applied Biosystems).
Transfection of Lymphoma Cells and Luciferase Assay—The
egr-1-encoding plasmid pBX-Egr1 or various egr-1 promoterdriven firefly luciferase constructs (p903luc, p395luc, p242luc,
and LucA–D) were introduced into BKS-2 cells by electroporation. For electroporation, BKS-2 cells were washed and resuspended in cold Opti-MEM I. The cells were then mixed with the
indicated amount of DNA and electroporated at 250 mV, 960
microfarads, and 200 ohms with a Gene Pulser electroporator
(Bio-Rad). For ectopic Egr-1 expression experiments, 1 day
post-electroporation, BKS-2 cells transfected with pBX-Egr1 or
a control vector were counted, and an equal number of cells
with the indicated treatment were used to set up the proliferation assay as described. For luciferase assay, BKS-2 cells were
washed once and rested at 37 °C in IF-12 medium containing
10% FCS for 1 h post-electroporation. After that, BKS-2 cells
were plated at ⬃1 ⫻ 105/well into 96-well flat-bottom microtiter plates in 200 l of IF-12 medium containing 10% FCS with
various treatments added and incubated at 37 °C for 6 h. Cells
were spun down and lysed in the plate with 20 l of cell lysis
buffer at room temperature for 5 min. Firefly and Renilla luciferase activities were measured on an LMax luminometer
(Molecular Devices Corp., Sunnyvale, CA) using a firefly and
Renilla luciferase assay kit (Biotium Inc., Hayward, CA).

Mechanism of BCR-induced Down-regulation of Egr-1
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underwent down-regulation with
time. This suggests that, being an
immediate-early gene, egr-1 expression is tightly regulated in lymphoma cells. We postulate that the
expression of egr-1 may be cell cycledependent and required only during
early phases of the cell cycle. Once it
exerts its function, Egr-1 is downregulated to allow cells to progress
into other phases of the cell cycle.
Direct inhibition of Egr-1
reduced the growth of BKS-2 cells,
whereas anti-IgM antibody-mediated growth inhibition of BKS-2
cells was accompanied by downregulation of Egr-1. In this study, we
found that PMA, a potent protein
kinase C activator, was able to rescue the anti-IgM antibody-induced
FIGURE 3. Ectopic expression of Egr-1 partially overcomes anti-IgM antibody-induced growth inhibition.
BKS-2 cells were transfected with either a control vector plasmid (pEGFP-N1) or an egr-1-encoding plasmid growth inhibition of BKS-2 cells in a
(pBX-Egr1) by electroporation. 1 day after electroporation, cells were counted, and an equal number of cells dose-dependent manner (Fig. 2C).
(2 ⫻ 104/well) were plated in 200 l of medium supplemented with 10% FCS in a 96-well plate with or without Although the ability of PMA to resthe indicated anti-IgM antibody treatment. Cell proliferation was determined as described in the legend to Fig.
2. Data points indicate the mean counts ⫾ S.E. of triplicate cultures. * and #, p ⬍ 0.001 for BKS-2 cells transfected cue B lymphoma from BCR-inwith pBX-Egr1 compared with BKS-2 cells transfected with the control vector. This experiment was repeated duced growth inhibition has been
once with a similar outcome.
reported before in WEHI-231 cells
(45), its effect on egr-1 expression in
nant-negative inhibitor of Egr-1 containing the repressor domain B lymphoma cells has not been reported. We examined whether
from the Wilms tumor gene and the three zinc finger DNA-bind- PMA can overcome anti-IgM antibody-induced down-regulation
ing motifs from Egr-1 (28), inhibited the basal proliferation of of Egr-1 protein in BKS-2 cells. Indeed, we found that the anti-IgM
both BKS-2 (Fig. 1B) and CH12.Lx (Fig. 1C) lymphoma cells. antibody-induced down-regulation of egr-1 expression was
Western blot analyses using an antibody against the N-terminal reversed by PMA treatment, which was accompanied by robust
domain of WT1 protein detected the expression of a ⬃45-kDa proliferation of BKS-2 cells even in the presence of anti-IgM antiprotein, corresponding to the molecular mass of WT1-EGR1, body (Fig. 2C). These data suggested that protein kinase C is
in both BKS-2 and CH12.Lx cell lines transfected with the upstream of Egr-1 and support that Egr-1 has an important role in
WT1-EGR1-encoding retrovirus, but not with the GFP-only promoting the growth and proliferation of B lymphoma cells.
Ectopic Expression of Egr-1 Partially Rescues Anti-IgM Anticontrol vector (Fig. 1, B and C). Interestingly, irrespective of the
WT1-EGR1 protein expression status, Egr-1 protein was body-induced Growth Inhibition—To further establish the
expressed in both BKS-2 and CH12.Lx cells (Fig. 1, B and C). importance of Egr-1 for B cell proliferation, a plasmid encoding
The level of Egr-1 was slightly reduced upon WT-EGR1 expres- the full-length Egr-1 cDNA driven by the SV40 promoter was
sion. Because WT1-EGR1 is a functional inhibitor of Egr-1 transiently transfected into BKS-2 cells by electroporation.
(inhibits the downstream targets of Egr-1), it may indirectly After 1 day, cells were washed and treated with or without antiinhibit egr-1 expression. These two experiments firmly estab- IgM antibody for 48 h, and proliferation was measured. As
shown in Fig. 3, 0.2 g/ml anti-IgM antibody strongly inhibited
lish the importance of Egr-1 for B lymphoma cell growth.
Up-regulation of Egr-1 by Phorbol 12-Myristate 13-Acetate the growth of BKS-2 cells, and BKS-2 cells transfected with the
(PMA) Rescues BCR-mediated Growth Inhibition of BKS-2 Egr-1 plasmid exhibited partial restoration of proliferation in
Cells—Anti-IgM antibody-mediated cross-linking of BCR comparison with BKS-2 cells transfected with the control vecinduces growth arrest and apoptosis of several immature B lym- tor. This increase in proliferation is statistically significant (p ⬍
phoma cells, including BKS-2 (38, 44). In agreement with the 0.001) and was dose-dependent on the Egr-1 plasmid. We also
previous results, rat anti-mouse IgM monoclonal antibody performed similar experiments using WEHI-231 cells and
(AK11) inhibited BKS-2 proliferation in a dose-dependent demonstrated that ectopic expression of Egr-1 in WEHI-231
manner (Fig. 2A). Western blot analysis showed that, at early cells also partially reversed anti-IgM antibody-mediated
time point (1 h), BCR cross-linking did not appreciably affect growth inhibition (data not shown). These experiments collecEgr-1 protein expression compared with the untreated group tively suggest that Egr-1 has a pro-growth role in B lymphoma
(Fig. 2B). At later time points (5 and 24 h), BCR cross-linking cells.
significantly down-regulated Egr-1 protein compared with the
Egr-1 mRNA Stability Is Not Affected by BCR Cross-linking—
untreated group (Fig. 2B). Consistent with its nature as an Because Egr-1 plays an important role in B lymphoma cell
immediate-early gene, Egr-1 protein in the untreated group growth, we next wanted to understand how Egr-1 mRNA is
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synthesized. Labeled RNA was hybridized to filters containing Egr-1 and
c-Myc cDNAs or empty vector. The amount of mRNA hybridizing to each
target was analyzed by dot blot analysis.
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FIGURE 4. Regulation of egr-1 by BCR cross-linking is at the transcriptional level. A, Egr-1 mRNA is down-regulated by anti-IgM antibody. BKS-2
cells were cultured with or without anti-IgM antibody for 30 min. Total RNA
was isolated, and Egr-1 and GAPDH mRNAs were quantified by real-time PCR
as described under “Experimental Procedures.” The results are representative
of three independent experiments. *, p ⬍ 0.01 versus the medium group.
B, Egr-1 mRNA stability is not affected by BCR cross-linking. BKS-2 cells were
cultured with or without anti-IgM antibody for 1 h and then treated with 5
g/ml actinomycin D for 30, 60, and 90 min. Total RNA was isolated, and Egr-1
and GAPDH mRNAs were quantified by real-time PCR as described under
“Experimental Procedures.” The Egr-1 level was normalized to the GAPDH
level and is plotted versus time. Two exponential (Expon.) curves were fitted to
the data points. The slopes of the two lines are 0.018 and 0.017, and R2 is
⬎0.94 for both lines. A representative of two independent experiments is
shown. C, transcription of egr-1 is reduced by anti-IgM antibody (Ab). Nuclei
were isolated from BKS-2 cells treated with or without anti-IgM antibody for
1 h. Nuclei were incubated with [32P]UTP to label the mRNA being newly

regulated in BKS-2 cells by BCR cross-linking. Consistent with
previous Northern results (14), real-time PCR analysis showed
that anti-IgM antibody treatment of BKS-2 cells induced downregulation of Egr-1 mRNA compared with the medium group
(Fig. 4A). To determine whether BCR-mediated down-regulation of Egr-1 mRNA is due to its effect on Egr-1 mRNA stability,
Egr-1 mRNA levels were measured after blocking the transcription. BKS-2 cells were treated with or without anti-IgM antibody for 1 h, and then 5 g/ml actinomycin D was added to
block the transcription. Total RNA was extracted from BKS-2
cells collected at different time points following actinomycin D
treatment. Egr-1 mRNA in each sample was quantified by realtime PCR and normalized to GAPDH mRNA. Least-square
analysis was used to fit a straight line to the data points. The two
lines appear parallel (Fig. 4B). The rate of Egr-1 mRNA decay
was very similar with or without anti-IgM antibody treatment,
suggesting that Egr-1 mRNA stability is not appreciably
affected by BCR cross-linking.
egr-1 Transcription Is Down-regulated by BCR Cross-linking—
To determine whether BCR-mediated down-regulation of Egr-1
mRNA and expression is regulated at the level of transcription,
we used a nuclear run-on assay to measure the transcription
rate of egr-1 in the presence and absence of anti-IgM antibody
cross-linking. Nuclei were isolated from BKS-2 cells treated
with or without anti-IgM antibody for 1 h and used for in vitro
transcription. As shown in Fig. 4C, the transcription of egr-1
and c-myc was down-regulated by ⬃70% and ⬃60%, respectively, by anti-IgM antibody compared with the control antibody-treated group, suggesting that egr-1 transcription is
affected by BCR cross-linking.
High Egr-1 Protein Expression Levels in BKS-2 Lymphoma
Cells Are Dependent on JNK and ERK Activities—The p21ras/
Raf-1/MAPK pathway has been implicated in the induction of
egr-1 by BCR signaling in normal splenic B lymphocytes (27). It
is not clear whether MAPK activation has a role in the constitutive expression of egr-1 in B lymphoma cells. We used specific
pharmacological inhibitors to block each MAPK activity to
determine its role in constitutive egr-1 expression in transformed B cells. By Western blot analysis, we found that inhibition of JNK activity by SP600125 partially reduced Egr-1 protein (⬃40% reduction) (Fig. 5). Treatment of BKS-2 with
PD98059, an inhibitor of MEK1/2 upstream of ERK, strongly
inhibited Egr-1 protein (⬃80% reduction) (Fig. 5). Interestingly,
treatment of BKS-2 with SB203580, a p38 MAPK inhibitor,
resulted in up-regulation of Egr-1 protein (⬃40% increase).
These data suggest that the three MAPKs differentially regulate
Egr-1 protein levels. JNK and ERK are positive regulators of
Egr-1, whereas p38 MAPK is a negative regulator.
Blocking ERK Activity Inhibits the Growth of BKS-2 Cells—
The role of JNK in the growth and survival of B lymphoma cells
has been studied before (31). It was also shown that PD98059
does not appreciably inhibit the growth of BKS-2 cells (31).
Because ERK is a major regulator of Egr-1 expression, we examined the effect of ERK on BKS-2 cell growth more carefully. In
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revealed multiple potential regulatory DNA elements (Fig. 7A), most
notably the five SREs along with
adjacent Ets motifs that have been
demonstrated experimentally to
play an important role in up-regulation of egr-1 transcription in normal
B cells by BCR cross-linking (34). To
understand the contributions of the
cis-DNA elements in the egr-1 promoter region to constitutive egr-1
transcription, DNA constructs conFIGURE 5. A, constitutive Egr-1 protein expression is regulated by MAPK in BKS-2 cells. BKS-2 cells (4 ⫻ 106) were taining different truncations of the
treated with the JNK inhibitor SP600125, the p38 MAPK inhibitor SB203580, or the MEK1/2 inhibitor PD98059
at 20 M for 5 h at 37 °C. Cells were harvested and lysed. Protein lysates were analyzed by Western blotting egr-1 promoter linked to a firefly
using anti-Egr-1 antibody. The same blot was stripped and reprobed for ␤-actin as a loading control. B, densi- luciferase gene (p903luc, p395luc,
tometry of the Egr-1 band versus the actin band for the actual Western blot. The results are representative of
and p242luc) were used (Fig. 7B).
three experiments.
BKS-2 cells were transiently transfected with the p903luc, p395luc, and p242luc DNA constructs,
containing five, four, and two SREs, respectively, along with the
pActinRluc construct, and the firefly and Renilla luciferase
activities were measured at 6 h. To ensure equal transfection
efficiency between groups, the egr-1 promoter-driven firefly
luciferase activity was normalized to the actin promoter-driven
Renilla luciferase activity. Consistent with constitutive egr-1
expression in BKS-2 cells, the egr-1 promoter-driven luciferase
gene was abundantly expressed in BKS-2 lymphoma cells (Fig.
7B). Compared with p903luc, there was an ⬃50 – 60% reduction in the normalized egr-1 promoter activity for p395luc and
an ⬃80% reduction in the normalized egr-1 promoter activity
for p242luc. Using luciferase expression as a measure of contribution to transcription by each SRE, SRE5 and the upstream
FIGURE 6. Blocking ERK activity inhibits the growth of BKS-2 cells. BKS-2 region appear to contribute ⬃50 – 60% to constitutive Egr-1
cells (3 ⫻ 104/well) were cultured with the indicated concentrations of the transcription. SRE3/4 and SRE1/2 each contribute ⬃20% to
MEK1/2 inhibitor PD98059 or U0126 for 48 h. Because of the instability of the constitutive Egr-1 transcription. To further investigate whether
inhibitors in culture, the MEK1/2 inhibitor was added at half of the indicated
concentration at 0 and 24 h. Cells were pulsed with [3H]thymidine during the SRE5 and its adjacent Ets motif or the region farther upstream
last 4 h of culture. Data points indicate the mean ⫾ S.E. of the percent [3H] plays a more important role, BKS-2 cells were transiently transincorporation compared with the medium group of triplicate cultures from a fected with another set of egr-1 promoter-luciferase constructs
representative experiment. This experiment was repeated three times with
similar results. The actual counts for the medium group were 73,559 ⫾ 8092 (LucA–D) (Fig. 7C), and the firefly and Renilla luciferase activcpm.
ities were measured. LucA contains the 1.2-kb egr-1 promoter
region; LucB contains the egr-1 promoter upstream region
the previous study, a single treatment of PD98059 was used. without any SREs; LucC contains five SREs; and LucD contains
Gauld et al. (29) reported that neither PD98059 nor U0126 was only the three distal SREs (Fig. 7C). Upon comparison of the
stable in 2–3 day cultures of WEHI-231 cells. To inhibit egr-1 promoter activities of LucB and LucC with that of LucA, it
MEK1/2 over a long period of time (48 h), in this study, we is evident that the majority of egr-1 promoter activity is contribsubjected the cells to multiple treatments with these reagents. uted by the five SREs and adjacent Ets motifs (⬃80%). This rules
As shown in Fig. 6, the growth of BKS-2 cells was inhibited by out a significant role played by the farther upstream region of
multiple treatments with two different pharmacological inhib- the egr-1 promoter (beyond 425 bp) in egr-1 transcription
itors of MEK1/2 (PD98059 and U0126) in a dose-dependent (10⬃20%). Comparison of the promoter activities of LucC and
manner. U0126 was more effective than PD98059 as shown by LucD suggests that the removal of SRE1 and SRE2 caused a
the lower dose of U0126 required to reach the same extent of further ⬃20 –30% reduction in egr-1 transcription. These data
inhibition as PD98059. This suggests that sustained ERK activ- collectively suggest that five SREs differentially contribute to
ity is required for BKS-2 cell growth, presumably by activating egr-1 transcription with the order of SRE5 ⬎ SRE1 ⫹ 2 ⬵
SRE3 ⫹ 4.
downstream targets like Egr-1.
egr-1 Promoter Activity Is Dependent on JNK and ERK
Role of Five Serum Response Elements (SREs) in Constitutive
egr-1 Transcription—egr-1 is constitutively expressed in BKS-2 Activities—To understand how ERK and JNK activate Egr-1
cells presumably through constitutively active transcription. protein expression, we investigated whether transcriptional
Analysis of the 903-bp egr-1 promoter region by the computer activation of egr-1 is dependent on ERK and JNK activities.
program TESS (transcription element search system) (46) BKS-2 cells were transiently transfected with the p903luc DNA
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construct and then treated with three MAPK inhibitors for 6 h,
and luciferase activity was measured afterward. The egr-1 promoter-driven reporter gene activity was reduced by ⬃50% upon
PD98059 treatment and by ⬃20% upon SP600125 treatment,
whereas SB203580 treatment slightly increased the reporter
gene activity, which is statistically significant (Fig. 8A). Inhibition of both ERK and JNK activities had an additive effect on
inhibition of egr-1 transcription (⬃75% reduction) (Fig. 8A).
This suggests that ERK and JNK activate egr-1 transcription to
allow constitutive expression of Egr-1 protein, whereas p38
MAPK slightly inhibits egr-1 transcription.
ERK Activates egr-1 Transcription through the Five SREs—
Because ERK has a major role in egr-1 transcription, we further
investigated what regions in the egr-1 promoter are important in
ERK-mediated transcriptional activation of egr-1. BKS-2 cells were
transiently transfected with LucA–D along with pActinRluc and
then treated with 25 M PD98059 for 6 h. The promoter activities
of LucA, LucC, and LucD were inhibited by PD98059 treatment,
whereas that of LucB was not affected (Fig. 8B). LucA and LucC
DECEMBER 29, 2006 • VOLUME 281 • NUMBER 52

contain five SREs, and LucD contains three SREs, whereas LucB
does not contain any SREs. This suggests that ERK activates egr-1
transcription through the five SREs in the egr-1 promoter region.
BCR Cross-linking Down-regulates Three MAPK Activities in
Immature B Lymphoma Cells but Up-regulates ERK Activity in
Splenic Immature B Cells—Because constitutive egr-1 transcription and protein levels are dependent on ERK and JNK
activities, we investigated whether BCR-induced Egr-1 downregulation could be due to its effect on MAPK activation. The
three MAPK activities in response to BCR cross-linking were
measured by Western blotting. At 1 h after BCR cross-linking,
there was a significant reduction in JNK and p38 activities
(defined as the ratio of phospho-MAPK to total MAPK) and a
small reduction in ERK activity (Fig. 9). The Egr-1 protein level
was not appreciably down-regulated at 1 h. This could be due to
a delay of the effect of BCR signaling on Egr-1 protein levels.
Also because the p38 MAPK inhibitor enhanced Egr-1 expression (Fig. 5), this early reduction in p38 MAPK activity may
have a role in BCR-induced stabilization of Egr-1 protein levels.
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 7. egr-1 transcription is dependent on the five SREs in the egr-1 promoter region. A, diagram of p903luc depicting some putative DNA elements
in the 903-bp egr-1 promoter region. B, diagram of the different truncations of egr-1 promoter-luciferase (Luc) constructs with each of the five SREs shown as
a square (left panel) and measured egr-1 promoter activity (right panel). BKS-2 cells were transiently transfected with p903luc, p395luc, p242luc, or the
promoterless firefly luciferase construct pluc along with pActinRluc by electroporation. The cells were rested for 1 h and incubated with IF-12 medium
containing 5% FCS for 6 h. The cells were harvested and lysed. The cell lysates were assayed for luciferase activity as described under “Experimental Procedures.” Data are representative of two independent experiments. *, p ⬍ 0.01 versus the p903luc group. C, diagram of the different truncations of egr-1
promoter-luciferase constructs (LucA–D) (left panel) and measured egr-1 promoter activity (right panel). The experiment details are similar to those described
for B. *, p ⬍ 0.01 versus the LucA group.
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At 5 h after BCR cross-linking, despite a decrease in p38 MAPK
activity, ERK was further down-regulated, which, together with
the reduced JNK activity, may account for the drop in Egr-1
protein upon BCR cross-linking (Fig. 2B and 9). At 24 h, JNK
activity was almost undetectable, although some residual ERK
activity could be detected. At this time point, p38 MAPK activity was similar in the anti-IgM antibody-treated and untreated
groups because of down-regulation of p38 activity in the
untreated group. The down-regulation of ERK and JNK activities at 24 h caused a significant reduction in Egr-1 protein (Fig.
2B and 9). These data suggest that BCR-mediated signaling
down-regulates all three MAPK activities and that the downregulation of ERK and JNK activities causes the down-regulation of Egr-1 protein.

39814 JOURNAL OF BIOLOGICAL CHEMISTRY

DISCUSSION
Previous studies in our laboratory demonstrated that the
murine B lymphoma cell line BKS-2 constitutively expresses
egr-1 and that BCR cross-linking leads to strong growth inhibition accompanied by a reduction in Egr-1 mRNA (14, 22). This
pro-growth-inducing property of Egr-1 in B lymphoma cells is
in contrast to its role in suppressing tumor transformation in
several human tumor cell lines, including fibrosarcoma, breast
carcinoma, and glioblastoma cells, and its role in ionizing radiation-induced growth inhibition in human melanoma cells (15,
47, 48). Hence, we further investigated the prosurvival role of
Egr-1 in B lymphoma cells. In this study, we have demonstrated
VOLUME 281 • NUMBER 52 • DECEMBER 29, 2006

Downloaded from http://www.jbc.org/ by guest on February 20, 2019

FIGURE 8. A, egr-1 promoter activity is dependent on ERK and JNK activities.
BKS-2 cells were transiently transfected with p903luc by electroporation. The
cells were then rested for 1 h and treated with the JNK inhibitor SP600125, the
p38 MAPK inhibitor SB203580, the MEK1/2 inhibitor PD98059, or the JNK and
MEK1/2 inhibitors at 20 M each for 6 h. The cells were harvested and lysed.
The cell lysates were assayed for luciferase (Luc) activity as described under
“Experimental Procedures.” A representative of three independent experiments is shown. In these experiments, the same population of electroporated
cells was used for different treatments. *, p ⬍ 0.001 versus the medium group;
#, p ⬍ 0.05 versus the medium group. B, ERK activates egr-1 transcription
through the five SREs. BKS-2 cells were transiently transfected with LucA–D as
indicated along with pActinRluc by electroporation. The cells were then
rested for 1 h and treated with or without 20 M PD98059 for 6 h. The cells
were harvested and lysed. The cell lysates were assayed for luciferase activity
as described under “Experimental Procedures.” A representative of two independent experiments is shown.

The above data show that MAPKs are constitutively active in
immature B lymphoma cells and that BCR cross-linking causes
down-regulation of MAPK activities. To investigate whether
the three MAPKs are also constitutively active in normal immature B cells and how MAPK activities are regulated by BCR
cross-linking, we measured the levels of phospho-MAPK in
normal immature B cells stimulated by BCR cross-linking for
different time periods. Immature B cells were isolated from
neonatal mice because, compared with young adult mice, splenic B cells from neonatal mice (9 –12 days old) were predominantly immature as judged by B220, AA4.1, CD43, and IgM
FACS staining (data not shown). Thus, immature B cells were
purified from one litter of neonatal mice as described under
“Experimental Procedures.” As shown in Fig. 10, the levels of
phosphorylated ERK, JNK, and p38 MAPK were low or undetectable without stimulation (0-h time point), in contrast to the
constitutive activation of MAPK in immature B lymphoma cells
such as BKS-2. Anti-IgM antibody-induced a transient increase
in ERK activity at an early time point (25 min), but this
increased activity of ERK was not sustained and was much
reduced at 1–5 h, returning to the basal level at 24 h. There was
a small induction of ERK activity at 5 h for the medium group,
which was also not sustained at later time points. BCR crosslinking had only minor effects on the levels of phospho-JNK
and phospho-p38 in immature B cells at all time points tested. A
slight elevation of JNK and p38 activities was observed, which
was not sustained. The data suggest that, in immature B cells,
BCR cross-linking causes rapid but transient up-regulation of
ERK with minimal effects on JNK and p38. More interestingly,
there is a strong correlation between the induction of ERK
activity and the induction of Egr-1 protein just as we observed
for the lymphoma cell lines. ERK activity was maximum at 25
min, whereas Egr-1 reached its maximum at ⬃1 h (Fig. 10B).
The reduction in ERK activity at later time points was followed
by reduced levels of Egr-1 at 5 h and undetectable levels later on.
Despite this Egr-1 expression, immature B cells are known to be
deficient in proliferation in response to BCR cross-linking. So
we wondered if this Egr-1 level is not optimum for proliferation.
Immature B cells had one-half to one-third the amount of Egr-1
protein in BKS-2 cells (data not shown). For comparison with
mature B cells, we performed real-time PCR analysis of Egr-1
mRNA in mature B cells from adults and immature B cells from
neonates stimulated by BCR cross-linking. As shown in Fig.
10C, the Egr-1 message level in immature B cells was half of that
in mature B cells between 30 min and 3 h.
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study the role of three MAPKs
(ERK, JNK, and p38) in maintaining
constitutive egr-1 expression in
BKS-2 cells. We found that the constitutive expression of egr-1 in this
lymphoma cell line is dependent
mainly on ERK activity and partially
dependent on JNK activity. Because
ERK and JNK phosphorylate downstream targets such as c-Myc, Elk-1,
Stat1/3 (signal transducer and activator of transcription), c-Jun, and
activating transcription factor-2,
which are transcription factors, we
studied the transcriptional regulation of egr-1 in BKS-2 cells. The
903-bp egr-1 promoter region has a
number of putative DNA elements
(Fig. 7A). Using different truncations of the egr-1 promoter linked to
the firefly luciferase gene, we found
that constitutive egr-1 transcription
is dependent mainly on the five
SREs, with SRE5 having the most
important role. McMahon and
Monroe (34) reported the preferential usage of SRE3 and SRE4 along
with adjacent Ets motifs in BCRmediated up-regulation of egr-1
transcription in normal B cells. It
appears that all five SREs contribute
to constitutive egr-1 transcription in
FIGURE 9. JNK and ERK activities are down-regulated by BCR cross-linking. BKS-2 cells (4 ⫻ 106) were B lymphoma cells. Transient
cultured in the absence or presence of 5 g/ml anti-IgM antibody for 1, 5, and 24 h. Cells were harvested and
lysed. Protein lysates were analyzed by Western blotting using anti-phosphorylated (p) ERK, JNK, and p38 expression of a 903-bp egr-1 proMAPK antibodies. The same blot was stripped and reprobed for total JNK, ERK, and p38 MAPK as a loading moter-driven luciferase construct
control. The phospho-JNK/JNK, phospho-ERK/ERK, and phospho-p38 MAPK/p38 MAPK ratios are plotted ver- and treatment with MAPK inhibisus time and shown below the actual Western blots. Data are representative of three independent
tors demonstrated that ERK and
experiments.
JNK regulate Egr-1 at the transcriptional level. Moreover, the ERK-methat inhibition of Egr-1 leads to inhibition of BKS-2 cell growth diated transcriptional activation of egr-1 is mediated through
using either an antisense ODN for Egr-1 or retrovirus-mediated the five SREs (Fig. 8B). In normal B cells, a ternary complex
expression of a dominant-negative inhibitor of Egr-1. More- composed of a homodimer of serum response factors and a
over, we found that PMA-induced overexpression of Egr-1 or member of the Ets family of transcription factors called the
ectopic expression of Egr-1 cDNA by a plasmid vector can over- ternary complex factor mediates induction of egr-1 transcripcome anti-IgM antibody-induced growth inhibition. These tion (34). We postulate that constitutively active ERK or JNK
data collectively support the proposal that Egr-1 acts as a can phosphorylate the ternary complex factor (such as Elk-1)
growth stimulator for B lymphoma cells and that reduction of and the serum response factor, which form a ternary complex
Egr-1 levels (antisense ODN) or function (dominant-negative and bind to the five SREs, mainly SRE5, on the egr-1 promoter
approach) leads to growth inhibition. Consistent with our data, to activate its transcription. Our data also show that p38 MAPK
Egr-1 has been found to play an important role in many trans- negatively regulated Egr-1 at the protein level. Recently, it was
formed cells, including human prostate cancer (12), Nb2 lym- shown that erythropoietin-induced expression of Egr-1 is
inhibited by MEK1/2 inhibitors but enhanced by a p38 MAPK
phoma (49), and body cavity BC-2 lymphoma (13) cells.
Several studies using different cell lines reported that the inhibitor in murine erythroleukemia cells (25). It was shown
up-regulation of Egr-1 by various stimuli, including estrogen, that inhibition of p38 MAPK by SB203580 has a stimulatory
lipopolysaccharide, erythropoietin, T cell receptor, and BCR, is effect on the ERK1/2 MAPK pathway. In B lymphoma cells, the
mediated through the Ras/Raf-1/MEK/ERK pathway (19, p38 MAPK inhibitor slightly increases egr-1 transcription. The
24 –27). In many lymphoma cells, including BKS-2 cells, MAPK up-regulation of Egr-1 protein by the p38 MAPK inhibitor may
activities are constitutively active (31). This prompted us to be partly through an increase in egr-1 transcription in B lym-
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phoma cells, although other post-transcriptional regulatory
mechanisms may also exist.
Different BCR-mediated responses in mature and immature
B cells have been studied for a long time, and several mechanisms have been proposed to account for BCR-mediated apoptosis in immature B cells, including defective BCR translocation into lipid rafts, lower levels of B cell coreceptors such as
CD19 and CD22, inability to activate protein kinase C, and
defective activation of adapter molecules such as Gab1/2 (50 –
52). In particular, several studies have indicated that BCR-induced ERK1/2 activity plays an important role in both the survival and apoptosis of immature B cells. Lee and Koretzky (53)
reported that ERK2 is involved in mediating anti-IgM antibodyinduced apoptosis of WEHI-231 cells. Koncz et al. (52) reported
that BCR cross-linking induces only transient ERK1/2 phosphorylation in immature B cells but sustained ERK1/2 phosphorylation in mature B cells. Gauld et al. (29) reported that, in
the immature B cell line WEHI-231, BCR-mediated early activation of ERK (ⱕ2 h) activates the phospholipase A2 pathway
and leads to apoptosis, whereas the sustained cycling pattern of
activation of ERK (8 – 48 h) leads to cell growth and prolifera-
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tion. In this study, we found that BCR cross-linking down-regulates all three MAPK activities, particularly the ERK and JNK
activities. Consistent with the report of Gauld et al., this suggests that BCR signaling inhibits the sustained activation of
ERK to inhibit cell growth and proliferation. Moreover, BCR
signaling also inhibits JNK activity, which was also shown to be
essential for B cell growth and survival in our recent study (31).
The data reported here suggest that the growth inhibition
induced by BCR signaling could be due to synergistic inhibition
of both ERK and JNK activities. This may also explain why
growth inhibition induced by ERK inhibitors alone is not as
potent as that induced by BCR ligation (Fig. 2A versus Fig. 6).
Because the constitutive activities of ERK and JNK are higher
than that of p38 MAPK and because p38 MAPK undergoes
spontaneous down-regulation with time (Fig. 9), p38 MAPK
may not play as significant a role as JNK and ERK, although it is
also down-regulated by BCR signaling. King et al. (51)proposed
the imbalance theory, which suggests that BCR signaling can
induce similar levels of calcium response in both mature and
immature B cells, but fails to activate protein kinase C in immature B cells, leading to apoptosis. Because protein kinase C is the
VOLUME 281 • NUMBER 52 • DECEMBER 29, 2006
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FIGURE 10. Regulation of MAPK activation and egr-1 expression by BCR cross-linking in immature and mature B cells. A, BCR-induced MAPK activation
in immature B cells. Immature B cells (3 ⫻ 106) were cultured in the absence or presence of 20 g/ml anti-IgM antibody for 25 min and 1, 5, and 24 h. Cells were
harvested and lysed. Protein lysates were analyzed by Western blotting using anti-phosphorylated (p) JNK, ERK, and p38 MAPK antibodies. The same blot was
stripped and reprobed for total JNK, ERK, and p38 MAPK as a loading control. B, BCR-induced egr-1 expression in immature B cells. The same lysates as described
for A were analyzed by Western blotting using anti-Egr-1 antibody. The same blot was stripped again and reprobed for actin as a loading control. C, BCR
cross-linking induces lower Egr-1 mRNA levels in immature than in mature B cells. Splenic immature and mature B cells were isolated from neonatal and adult
mice, respectively. Cells (1 ⫻ 106) were cultured in the absence or presence of 50 g/ml anti-IgM antibody for different time periods, and total RNA was
subsequently isolated. Egr-1 and ␤-actin mRNAs were quantified by real-time PCR as described under “Experimental Procedures.” Data are representative of
two independent experiments.
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upstream enzyme of the three MAPKs, BCR signaling in immature B lymphoma cells may induce the down-regulation of protein kinase C activity, which then leads to the down-regulation
of the three MAPK activities. Consistent with this theory, the
BCR-induced growth inhibition is reversed by PMA, a protein
kinase C activator. Alternatively, the inhibition of MAPK activities could be due to BCR-induced up-regulation of MAPK
phosphatase activities (29, 54).
In contrast to immature B lymphoma cells, constitutive
MAPK activation was almost undetectable in resting immature
B cells. Upon BCR cross-linking, there was a transient increase
in ERK activity in immature B cells, in agreement with a previous report (52), but it was different from the sustained ERK
activation observed in mature B cells. Interestingly, the level of
Egr-1 was also transiently up-regulated with delayed kinetics, in
contrast to the higher and/or prolonged expression of Egr-1 in
mature B cells (4 –12 h at the protein level according to Seyfert
et al. (55)) or lymphoma cells (Fig. 2B). These results are consistent with the concept that a threshold level of Egr-1 may be
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